Literature DB >> 3845078

Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus.

R H Eng, S M Smith, F J Buccini, C E Cherubin.   

Abstract

Rifampicin resistance developed easily in methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus during an overnight incubation in broth containing 0.1 mg/l of rifampicin. Incubation of methicillin-susceptible Staph. aureus and 0.1 mg/l of rifampicin with 1 mg/l of nafcillin reduced the emergence of rifampicin resistance with only 5 of 50 strains (10%) becoming rifampicin-resistant. However, incubation of the methicillin-susceptible or methicillin-resistant strains with 0.1 mg/l of rifampicin and 1 mg/l of vancomycin did not prevent the development of rifampicin resistance. Rifampicin resistance developed in 25 of 50 (50%) of methicillin-susceptible and 32 of 50 (64%) methicillin-resistant Staph. aureus strains tested. These data would suggest that differences exist in the abilities of nafcillin and vancomycin to suppress the development of rifampicin resistance in Staph. aureus (P less than 0.01). Caution should be exercised when the combination of vancomycin and rifampicin is used for infections caused by Staph. aureus and Staph. aureus isolates recovered during therapy should be monitored for the development of rifampicin resistance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3845078     DOI: 10.1093/jac/15.2.201

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; Jacques Schrenzel; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

Authors:  Mukesh Patel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

4.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

Review 5.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.

Authors:  K Fujii; A Tsuji; S Miyazaki; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  Effective treatment of cephalosporin-rifampin combinations against cryptic methicillin-resistant beta-lactamase-producing coagulase-negative staphylococcal experimental endocarditis.

Authors:  C M Brandt; M S Rouse; B M Tallan; N W Laue; W R Wilson; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

8.  Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  A Cagni; C Chuard; P E Vaudaux; J Schrenzel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

9.  Synergism between Medihoney and rifampicin against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Patrick Müller; Dagmar G Alber; Lynne Turnbull; Ralf C Schlothauer; Dee A Carter; Cynthia B Whitchurch; Elizabeth J Harry
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.